TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

MLTX STOCK: Lose Money on Your MoonLake Immunotherapeutics Investment? Contact BFA Law about the Pending Securities Class Action before December 15 Deadline

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Bleichmar Fonti & Auld Llp
MLTX STOCK: Lose Money on Your MoonLake Immunotherapeutics Investment? Contact BFA Law about the Pending Securities Class Action before December 15 Deadline

MoonLake Immunotherapeutics faces a securities class action lawsuit after reporting disappointing Phase 3 VELA trial results for its investigational drug sonelokimab, causing its stock price to drop nearly 90%.

Insights
MLTX   negative

Stock price collapsed by 90% after failed clinical trials, with allegations of misleading investors about drug's clinical benefits and potential regulatory approval